DalsnaFinance

Crispr Therapeutics AG $CRSP

Health Care

Russell 2000 Switzerland
Create a scorecard
$49.88
-0.16 (-0.32%)
As of Oct 20, 2026, 6:42 PM EDT · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Jul 30, 2026, the first target we tracked for CRSP.

Crispr Therapeutics AG (CRSP) is trading down at $49.88 (-0.32%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.

IPO: October 19, 2016 · $14.00 offering · NASDAQ · View IPO details →

Analyst price targets on CRSP

Current price targets from 2 firms average $70, ranging from $60 to $80 — 40% above the current $49.9. Each is tracked to its date and scored the same way a member's call is.

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Crispr Therapeutics AG revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$915.0M$132.4M−$650.2MFY2016 revenue: $5.16MFY2016 net income: −$23.2M · Net margin −448.8%'16FY2017 revenue: $41.0MFY2017 net income: −$68.4M · Net margin −166.7%'17FY2018 revenue: $3.12MFY2018 net income: −$165.0M · Net margin −5281.1%'18FY2019 revenue: $289.6MFY2019 net income: $66.9M · Net margin 23.1%'19FY2020 revenue: $719.0KFY2020 net income: −$348.9M · Net margin −48520.9%'20FY2021 revenue: $915.0MFY2021 net income: $377.7M · Net margin 41.3%'21FY2022 revenue: $1.20MFY2022 net income: −$650.2M · Net margin −54271.7%'22FY2023 revenue: $371.2MFY2023 net income: −$153.6M · Net margin −41.4%'23FY2024 revenue: $37.3MFY2024 net income: −$366.3M · Net margin −981.5%'24FY2025 revenue: $3.51MFY2025 net income: −$581.6M · Net margin −16569.8%'25−71.1%−50%0%50%100%FY2016 net margin: −448.8% (off the scale, which stops at −71.1%)FY2017 net margin: −166.7% (off the scale, which stops at −71.1%)FY2018 net margin: −5281.1% (off the scale, which stops at −71.1%)FY2019 net margin: 23.1%FY2020 net margin: −48520.9% (off the scale, which stops at −71.1%)FY2021 net margin: 41.3%FY2022 net margin: −54271.7% (off the scale, which stops at −71.1%)FY2023 net margin: −41.4%FY2024 net margin: −981.5% (off the scale, which stops at −71.1%)FY2025 net margin: −16569.8% (off the scale, which stops at −71.1%)
Crispr Therapeutics AG annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$5.16M$41.0M$3.12M$289.6M$719.0K$915.0M$1.20M$371.2M$37.3M$3.51M
Growth (year over year)+1990.7%+693.9%−92.4%+9169.8%−99.8%+127154.9%−99.9%+30885.5%−89.9%−90.6%
Operating income−$68.1M−$64.6M−$158.9M$46.7M−$354.4M$373.5M−$673.2M−$222.5M−$466.6M−$664.6M
Operating margin−1319.3%−157.7%−5087.8%16.1%−49295.5%40.8%−56190.4%−60.0%−1250.4%−18933.6%
Net income−$23.2M−$68.4M−$165.0M$66.9M−$348.9M$377.7M−$650.2M−$153.6M−$366.3M−$581.6M
Net margin−448.8%−166.7%−5281.1%23.1%−48520.9%41.3%−54271.7%−41.4%−981.5%−16569.8%
EPS (diluted)−$1.89−$1.71−$3.44$1.17−$5.29$4.70−$8.36−$1.94−$4.34−$6.47
Balance sheet
Cash and equivalents$315.5M$239.8M$456.6M$943.8M$1.17B$923.0M$211.9M$389.5M$298.3M$347.6M
Total assets$345.0M$271.3M$489.0M$1.07B$1.83B$2.75B$2.24B$2.23B$2.24B$2.27B
Total liabilities$112.1M$83.5M$96.8M$127.3M$163.7M$352.4M$367.6M$346.8M$310.0M$343.4M
Long-term debt—————————$0
Shareholders' equity$232.8M$187.8M$392.2M$939.4M$1.66B$2.40B$1.88B$1.88B$1.93B$1.92B
Cash flow
Operating cash flow−$52.9M−$70.1M−$96.2M$56.7M−$238.4M$539.0M−$495.7M−$260.4M−$142.8M−$345.0M
Capital expenditure$3.02M$7.81M$2.77M$6.68M$18.4M$81.7M$37.2M$9.47M$1.90M$914.0K
Free cash flow−$55.9M−$77.9M−$99.0M$50.0M−$256.7M$457.3M−$532.9M−$269.8M−$144.7M−$345.9M
Share buybacks——$57.0K———————

From Crispr Therapeutics AG's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Crispr Therapeutics AG

Headquarters
Zug, Switzerland From SEC filings, Oct 2026

Recent News (15)

More Health Care stocks

Browse all companies →